WO2010075561A1 - Small molecule inhibitors of necroptosis - Google Patents

Small molecule inhibitors of necroptosis Download PDF

Info

Publication number
WO2010075561A1
WO2010075561A1 PCT/US2009/069483 US2009069483W WO2010075561A1 WO 2010075561 A1 WO2010075561 A1 WO 2010075561A1 US 2009069483 W US2009069483 W US 2009069483W WO 2010075561 A1 WO2010075561 A1 WO 2010075561A1
Authority
WO
WIPO (PCT)
Prior art keywords
optionally substituted
compound
pharmaceutically acceptable
stereoisomer
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/069483
Other languages
English (en)
French (fr)
Inventor
Junying Yuan
Emily S. Hsu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard University
Original Assignee
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA2772760A priority Critical patent/CA2772760A1/en
Priority to BRPI0923126-9A priority patent/BRPI0923126A2/pt
Priority to CN2009801569144A priority patent/CN102316735A/zh
Priority to AU2009329879A priority patent/AU2009329879A1/en
Priority to JP2011543689A priority patent/JP2012513481A/ja
Priority to US13/141,545 priority patent/US20120122889A1/en
Application filed by Harvard University filed Critical Harvard University
Priority to EP09835866A priority patent/EP2381775A4/en
Publication of WO2010075561A1 publication Critical patent/WO2010075561A1/en
Anticipated expiration legal-status Critical
Priority to US14/033,176 priority patent/US9586880B2/en
Priority to US15/427,699 priority patent/US20170305824A1/en
Priority to US16/055,898 priority patent/US20190135718A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C35/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C35/22—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system
    • C07C35/37—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system with a hydroxy group on a condensed system having three rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C33/38—Alcohols containing six-membered aromatic rings and other rings and having unsaturation outside the aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C07D215/08—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms with acylated ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/18—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Definitions

  • the invention relates to compounds and to cell death, in particular through necrosis and necroptosis, and regulation thereof by small molecules.
  • necrotic and/or necrotic pathways In many diseases, cell death is mediated through apoptotic and/or necrotic pathways. While much is known about the mechanisms of action that control apoptosis, control of necrosis is not as well understood. Understanding the mechanisms regulating both necrosis and apoptosis in cells is essential to being able to treat conditions, such as neurodegenerative diseases, stroke, coronary heart disease, kidney disease, and liver disease. A thorough understanding of necrotic and apoptotic cell death pathways is also crucial to treating AIDS and the conditions associated with AIDS, such as retinal necrosis.
  • Cell death has traditionally been categorized as either apoptotic or necrotic based on morphological characteristics (Wyllie et al., Int. Rev. Cytol. 68: 251 (1980)). These two modes of cell death were also initially thought to occur via regulated (caspase-dependent) and non-regulated processes, respectively. More recent studies, however, demonstrate that the underlying cell death mechanisms resulting in these two phenotypes are much more complicated and, under some circumstances, interrelated. Furthermore, conditions that lead to necrosis can occur by either regulated caspase- independent or non-regulated processes.
  • necroptosis One regulated caspase-independent cell death pathway with morphological features resembling necrosis, called necroptosis, has recently been described (Degterev et al., Nat. Chem. Biol. 1 :112 (2005)). This manner of cell death can be initiated with various stimuli (e.g., TNF- ⁇ and Fas ligand) and in an array of cell types (e.g., monocytes, fibroblasts, lymphocytes, macrophages, epithelial cells and neurons).
  • stimuli e.g., TNF- ⁇ and Fas ligand
  • Necroptosis may represent a significant contributor to and, in some cases, predominant mode of cellular demise under pathological conditions involving excessive cell stress, rapid energy loss, and massive oxidative species generation, where the highly energy- dependent apoptosis process is not operative.
  • necrostatins compounds capable of inhibiting necroptosis therapeutics.
  • the discovery of compounds that prevent caspase- independent cell death would also provide useful therapeutic agents for treating or preventing conditions in which necrosis occurs. These compounds and methods would be particularly useful for the treatment of neurodegenerative diseases, ischemic brain and heart injuries, and head trauma.
  • the invention features a series of heterocyclic derivatives that inhibit tumor necrosis factor alpha (TNF- ⁇ ) induced necroptosis.
  • the invention further features pharmaceutical compositions featuring necrostatins.
  • the compounds and compositions of the invention may also be used to treat disorders where necroptosis is likely to play a substantial role.
  • the invention features a compound having a structure according to the following formula:
  • each R H1 , R H2 , R H 3, Rm, RH5, RHIO. RH ⁇ , Xm, Z m , Z m , and n is as defined for Formula (I),
  • each R H9 , R H IO, RHII, RHI2, RH ⁇ , RHM, RHIS, RHI6, and R H17 is selected, independently from H, optionally substituted C 1-6 alkyl, optionally substituted C 3- ] O cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, or optionally substituted heteroaryl; n is an integer between 0-6; and o is 0 or 1 ; and when R H j is H, R m is H or CO 2 Me, R H3 is H, R H4 is unsubstituted phenyl or phenyl substituted with 1 , 2, or 3 substituents selected from methoxy, chloro, or fluoro, R H5 is CN, R H io is H, Z H1 is S, n is 1, X H2 is O, and Z H2 is NH, R H 17 is not H, methyl, methoxy, unsubstituted 2-
  • the compound has a structure according to Formula (I-B)
  • R H5 is selected from II, CN, each R HIO , R HI I J R- HI25 an d R H ⁇ is selected from H, optionally substituted
  • Ci -6 alkyl optionally substituted C 3-10 cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, or optionally substituted heteroaryl;
  • Z H1 is selected from a single bond or S;
  • Z H2 is selected from a single bond or NR H ⁇ ; and
  • X H2 is O or S; or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.
  • the compound has the following structure:
  • R H1 and R H3 are H.
  • R H5 is CN
  • R H]0 is H.
  • Z H1 is S. In some embodiments, Z H2 is NH,
  • R H4 is unsubstituted phenyl or phenyl having 1 , 2, 3, 4, or 5 substituents.
  • the phenyl includes 1, 2, or 3 substituents selected from F, Cl, or OR H1S , where each R H18 is, independently, selected from H or optionally substituted C 1-6 alkyl.
  • the phenyl is 2-fluorophenyl, 2-chlorophenyl, 4-fluorophenyl, 4-chlorophenyl, 2-methoxyphenyl, 3, 4, 5-trimethoxyphenyl, or 3, 4-dimethoxyphenyl.
  • R H ⁇ is optionally substituted heteroaryl.
  • heteroaryl selected from furan, thiophene, pyrrole, 1,2,3- thiadiazole, 1,2,4-thiadiazole, 1,2,3-oxadiazole or 1,2,5-oxadiazole, oxazole, benzoxazole, isoxazole, isothiazole, pyrazole, thiazole, benzthiazole, 1,2,4- triazole, 1,2,3-triazole, benzotriazole, pyridine, pyrimidine, pyrazines, quinoline, isoquinoline, purine, pyrazine, pteridine, 1,2,3-triazine, 1,2,4- triazine, 1,3,5-triazine, indole, 1,2,4,5-tetrazine, benzo[ ⁇ ]thiophene, benzo[c]thiophene, benzofuran, isobenzofuran,
  • each R A1 , R A3 , and R A4 is selected, independently, from H, optionally substituted C 1-6 alkyl, optionally substituted C 2-6 alkenyl, optionally substituted C 2- 6 alkynyl, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or R A i and R A4 combine to form a carbon-carbon double bond;
  • G A2 is absent or -(CR A n R A , 2 ) n -;
  • X A3 is absent or is O, S, or NR A s;
  • each R A8 and R A13 is selected, independently, from H, optionally substituted C 1-6 alkyl, optionally substituted Cs -1O cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, -C0R A14 , -CO 2 RAH, or -CONR A]4 R A15 ;
  • each R A9 , R A1 o, R A I U an( l R AI2 is selected, independently, from H, halogen, optionally substituted C 1-6 alkyl, optionally substituted C 2-6 alkenyl, optionally substituted C 2-6 alkynyl, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted
  • R A i and R A4 are H.
  • R A3 is unsubstituted phenyl.
  • R A3 is phenyl having 1, 2, 3, 4, or 5 substituents.
  • G A2 is absent.
  • X A3 is absent and R A7 is optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.
  • X A3 is NR A g and R A7 is optionally substituted C 3- 10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.
  • G A2 is CH 2 .
  • X A3 is S and R A7 is optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.
  • X A3 is absent and R A7 is optionally substituted C 3-I o cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.
  • R A ] and R A4 combine to form a carbon-carbon double bond.
  • R A6 is optionally substituted aryl or optionally substituted heteroaryl.
  • R A6 is a phenyl group having a substituent at the 4-position.
  • R A2 is unsubstituted phenyl.
  • the invention features a compound having a structure according to the following formula:
  • R B2 is selected from H, optionally substituted C 1-6 alkyl, optionally substituted C 2-6 alkenyl, or optionally substituted C 2-6 alkynyl;
  • each R B5 , R B6 , R B7 , R B8 , R B9 , R B10 , R B11 , and R B]2 is selected
  • R B] is H.
  • R B2 is C ]-3 alkyl.
  • R B2 is C 1-3 alkenyl. In other embodiments, R B2 is ethynyl.
  • R B3 and R B4 are each H.
  • the compound has the following structure
  • R B2 is ethyl, ethenyl, or ethynyl and each R B9 , R B io, R B ⁇ , and R B]2 is selected, independently, from II and halogen, or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.
  • R B i 0 or R B i 2 is fluoro.
  • the compound has the following structure:
  • RB2 is ethyl, ethenyl, or ethynyl and each R ⁇ 9 , R B I O> R BI I , and R B12 is selected, independently, from H and halogen, or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.
  • the invention features a structure according to the following formula
  • Rc9 > Rcio > Rc ⁇ > an ⁇ Rci2 is selected, independently, from H, optionally substituted C 1-6 alkyl, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
  • Rc 4 is H, and R C5 and R C6 are H, R C3 is not -CH 2 (4-halophenyl); or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.
  • each R C5 and R C6 is optionally substituted C 1-6 alkyl.
  • the compound has a structure according to the following formula:
  • X is S.
  • n is 1.
  • Rc 3 is -Y-Rc 7 .
  • R C3 is (CH 2 )-(optionally substituted aryl).
  • the invention features a compound having a structure according to the following formula
  • A is phenyl having 0, 1, 2, 3, or 4 additional substituents;
  • Y DI and Y D2 are para to each other.
  • the compound has a structure according to the following formula
  • each R 02 , R D3 , R DI 7 , R DI S> R D I 9, and R 020 is selected, independently from H, halogen, CN, NC, N 3 , NO 2 , -COR D] 3 , -CO 2 R 0I3 , -CONR 013 R 014 , optionally substituted C ]-6 alkyl, optionally substituted aryl, or optionally substituted heteroaryl; and each R D9 and R D10 is selected, independently, from H, optionally substituted Ci -6 alkyl, optionally substituted C 3-1O cycloalkyl, or optionally substituted aryl, or R D9 and R D1O combine to form a heterocyclyl; or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.
  • Ron, RDIS, RDI 9 , and RD2 O are H.
  • R D2 and R 03 are H.
  • R D9 and R D10 are each optionally substituted C 1-6 alkyl.
  • the invention features a compound having a structure according to
  • each R E i, R E2 , and R K4 is selected, independently, from H, optionally substituted C J-6 alkyl, optionally substituted C 3-J0 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
  • R E3 is selected from optionally substituted C 3 . 10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; each R E6 and R E7 is selected, independently, from H or optionally substituted C 1 -6 alkyl; and each n is an integer between 1-6; and where when RE 1 and R E4 are H, Z E2 and Z E3 are each CH 2 , and R E2 is unsubstituted 3-indolyl, R E3 is not 4-chlorophenyl or CH 2 CH 2 O(p-C 6 H 4 F), or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.
  • the compound has a structure according to
  • R E3 is optionally substituted aryl or optionally substituted heteroaryl
  • R 9 is H, halogen, CN, NO 2 , OR 13 , NR 13 R 14 , COR 15 , CO 2 R 15 , or optionally substituted C 1-6 alkyl; each R 13 and R 14 is selected, independently, from H, COR 16 , CO 2 R 16 , optionally substituted C 1-6 alkyl, optionally substituted C 3-1O cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; and, each R 15 and R 16 is selected, independently, from H, optionally substituted C 1-6 alkyl, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.
  • R E3 is optionally substituted aryl.
  • R E3 is unsubstituted C 3-10 cycloalkyl, unsubstituted heterocyclyl, unsubstituted aryl, or unsubstituted heteroaryl.
  • R E3 is substituted C 3-10 cycloalkyl, substituted heterocyclyl, substituted aryl, or substituted heteroaryl.
  • the stereocenter marked by the asterisk in the compound of Formula (VI) has the ( ⁇ -configuration. In other embodiments, the stereocenter marked by the asterisk has the ( ⁇ -configuration.
  • the invention features a compound having a structure according to the following formula,
  • R F1 is selected from H, OR F14 , optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
  • R F2 and R F4 are each H, or R F2 and R F4 combine to form a carbon-carbon double bond; each R F6 , R F7 , R F8 , and R F9 is selected, independently, from H, halogen,
  • R F2 and R F4 are each H. In other embodiments, R F6 , R F7 , R F8 , and R F9 are H.
  • R n is optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.
  • each R 01 , R 02 , R 05 , and RQ 6 is selected, independently, from H, optionally substituted Ci -6 alkyl, optionally substituted C 3-J0 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or R 01 and R 02 , or RQ 5 and RQ 6 combine to form an optionally substituted cycloalkyl or heterocyclyl; and where when R 0J is unsubstituted phenyl and R 02 is H, R 05 and R 06 do not combine to form unsubstituted cyclopentyl; or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.
  • R G i or RQ 5 is phenyl having 0, 1, 2, 3, 4, or 5 substituents. In certain embodiments, R G i is unsubstituted phenyl. In some embodiments, R G2 or R G6 is phenyl having 0, 1, 2, 3, 4, or 5 substituents.
  • R G1 and R G2 , or R 05 and R 06 combine to form an optionally substituted cycloalkyl.
  • the cycloalkyl is cyclopropyl, cyclobutyl , cyclopentyl, or cyclohexyl.
  • the invention features a pharmaceutical composition including a pharmaceutically acceptable excipient and any compound of Formulas (I)-(VIII), or any of Compounds (l)-(7), (13)-(26), (27)-(33), (48)- (57), and (58)-(70), or any pharmaceutically acceptable salt or solvate thereof, or stereoisomer thereof.
  • the invention features a method of treating a condition in a subject, with the method including the step of administering the compound of any compound of Formulas (I)-(VIII), or any of Compounds (I)- (7), (13)-(26), (27)-(33), (48)-(57), and (58)-(70), or any pharmaceutically acceptable salt or solvate thereof, or stereoisomer thereof, to said subject in a dosage sufficient to decrease necroptosis.
  • the condition is a neurodegenerative disease of the central or peripheral nervous system, the result of retinal neuronal cell death, the result of cell death of cardiac muscle, the result of cell death of cells of the immune system; stroke, liver disease, pancreatic disease, the result of cell death associated with renal failure; heart, mesenteric, retinal, hepatic or brain ischemic injury, ischemic injury during organ storage, head trauma, septic shock, coronary heart disease, cardiomyopathy, myocardial infarction, bone avascular necrosis, sickle cell disease, muscle wasting, gastrointestinal disease, tuberculosis, diabetes, alteration of blood vessels, muscular dystrophy, graft- versus-host disease, viral infection, Crohn's disease, ulcerative colitis, asthma, or any condition in which alteration in cell proliferation, differentiation or intracellular signaling is a causative factor.
  • the condition is a neurodegenerative disease of the central or peripheral nervous system.
  • the condition is hepatic or brain ischemic injury, or ischemic injury during organ storage, head trauma, septic shock, or coronary heart disease. In some embodiments, the condition is stroke.
  • the condition is myocardial infarction.
  • the invention features a method of decreasing necroptosis, where the method includes contacting a cell with any compound of Formulas (I)-(VIII), or any of Compounds (I)-(O, (13)-(26), (27)-(33), (48)- (57), and (58)-(70)), or any pharmaceutically acceptable salt or solvate thereof, or stereoisomer thereof.
  • the invention features a kit including
  • a pharmaceutical composition comprising any compound of Formulas (I)-(VIII), or any of Compounds (l)-(7), (13)-(26), (27)-(33), (48)- (57), and (58)-(70), or any pharmaceutically acceptable salt or solvate thereof, or stereoisomer thereof; and (b) instructions for the use of the pharmaceutical composition of (a) to treat a condition in a subject.
  • the compound can be selected from the group consisting of:
  • C 1-4 alkaryl is meant a C 1-4 alkyl group having an optionally substituted aryl or an optionally substituted heteroaryl located at any position of the carbon chain.
  • the C 1-4 alkyl group may be linear or branched and may also be substituted with, for example, 1, 2, 3, 4, or 5 additional substituents as described herein.
  • alkoxy is meant a group having the structure -O(optionally substituted C 1-6 alkyl), where the optionally substituted C 1-6 alkyl may be branched, linear, or cyclic.
  • the C 1-6 alkyl may be substituted or unsubstituted.
  • a substituted C 1-6 alkyl can have, for example, 1, 2, 3, 4, 5, or 6 substituents located at any position.
  • Exemplary alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy, isopropoxy, tert-butoxy, and the like.
  • C 2-6 alkenyl or “alkenyl” is meant an optionally substituted unsaturated C 2-6 hydrocarbon group having one or more carbon-carbon double bonds.
  • a C 2-6 alkenyl may be linear or branched and may be unsubstituted or substituted.
  • a substituted C 2-6 alkenyl may have, for example, 1, 2, 3, 4, 5, or 6 substituents located at any position.
  • Ci -6 alkyl or “alkyl” is meant an optionally substituted C 1-6 saturated hydrocarbon group.
  • An alkyl group may be linear, branched, or cyclic ("cycloalkyl”).
  • alkyl radicals include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, sec-butyl, sec- pentyl, iso-pentyl, tert-butyl, n-pentyl, neopentyl, n-hexyl, sec-hexyl, n- heptyl, n-octyl, n-decyl, n-undecyl, dodecyl, and the like, which may bear one or more sustitutents.
  • Substituted alkyl groups may have, for example, 1, 2, 3, 4, 5, or 6 substitutents located at
  • C 2-6 alkynyl or “alkynyl” is meant an optionally substituted unsaturated C 2-6 hydrocarbon group having one or more carbon-carbon triple bonds.
  • exemplary C 2-6 alkynyl groups include, but are not limited to ethynyl, 1 -propynyl, and the like
  • amino is meant a group having a structure -NR'R", where each R' and R" is selected, independently, from H, optionally substituted C 1-6 alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or R' and R" combine to form an optionally substituted heterocyclyl.
  • R' and R" may be unsubstituted or substituted with, for example, 1, 2, 3, 4, 5, or 6 substituents.
  • aryl is meant is an optionally substituted C 6 -C 14 cyclic group with
  • Non-limiting examples of aryls include heteroaryls and, for example, benzene, naphthalene, anthracene, and phenanthrene.
  • Aryls also include bi- and tri-cyclic ring systems in which a non-aromatic saturated or partially unsaturated carbocyclic ring (e.g., a cycloalkyl or cycloalkenyl) is fused to an aromatic ring such as benzene or napthalene.
  • Exemplary aryls fused to a non-aromatic ring include indanyl, tetrahydronaphthyl,.
  • aryls as defined herein may be unsubstituted or substituted.
  • a substituted aryl may be optionally substituted with, for example, 1, 2, 3, 4, 5, or 6 substituents located at any position of the ring.
  • aryloxy is meant a group having the structure -O(optionally substituted aryl), where aryl is as defined herein.
  • azido is meant a group having the structure -N 3 .
  • carbamate or “carbamoyl” is meant a group having the structure -OCONR'R” or -NR 5 CO 2 R", where each R' and R" is selected, independently, from H, optionally substituted C 1-6 alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or R' and R" combine to form an optionally substituted heterocyclyl.
  • R' and R" may be unsubstituted or substituted with, for example, 1, 2, 3, 4, 5, or 6 substituents.
  • carbonate is meant a group having a the structure -OCO 2 R', where
  • R' is selected from H, optionally substituted C 1-6 alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.
  • R' is not H, R may be unsubstituted or substituted with, for example, 1, 2, 3, 4, 5, or 6 substituents.
  • R' and R" may be unsubstituted or substituted with, for example, 1, 2, 3, 4, 5, or 6 substituents.
  • carboxylic group is meant a group having the structure -CO 2 R', where R' is selected from H, optionally substituted C 1-6 alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.
  • R' is not H, R may be unsubstituted or substituted with, for example, 1, 2, 3, 4, 5, or 6 substituents.
  • cyano is meant a group having the structure -CN.
  • C 3 _ 10 cycloalkyl or “cycloalkyl” is meant an optionally substituted, saturated or partially unsaturated 3- to 10-membered monocyclic or polycyclic (e.g., bicyclic, or tricyclic) hydrocarbon ring system.
  • a cycloalkyl is polycyclic, the constituent cycloalkyl rings may be fused together, form a spirocyclic structure, or the polycyclic cycloalkyl may be a bridged cycloalkyl (e.g., adamantyl or norbonanyl) .
  • cycloalkyls induce cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl.
  • Cycloalkyls may be unsubstituted or substituted.
  • a substituted cycloalkyl can have, for example, 1, 2, 3, 4, 5, or 6 substituenls.
  • cycloalkenyl is meant a non-aromatic, optionally substituted 3- to 10-membered monocyclic or bicyclic hydrocarbon ring system having at least one carbon-carbon double bound.
  • a cycloalkenyl may have 1 or 2 carbon-carbon double bonds.
  • Cycloalkenyls may be unsubstituted or substituted.
  • a substituted cycloalkenyl can have, for example, 1, 2, 3, 4, 5, or 6 substituents.
  • Exemplary cycloalkenyls include, but are not limited to, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclopentadienyl, cyclohexenyl, 1,3-cyclohexadienyl, 1,4-cyclohexadienyl, and the like.
  • an effective amount or “therapeutically effective amount” of an agent is that amount sufficient to effect beneficial or desired results, such as clinical results, and, as such, an effective amount depends upon the context in which it is being applied.
  • an effective amount of an agent is, for example, an amount sufficient to achieve a reduction in necroptosis as compared to the response obtained without administration of the agent.
  • ester is meant a group having a structure selected from -OCOR', where R' is selected from H, optionally substituted C 1-6 alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.
  • R' is not H, R may be unsubstituted or substituted with, for example, 1, 2, 3, 4, 5, or 6 substituents.
  • halogen or halo is meant fluorine (-F), chlorine (-Cl), bromine (-Br), or iodine (-1).
  • heteroaryl is mean an aryl group that contains 1, 2, or 3 heteroatoms in the cyclic framework.
  • exemplary heteroaryls include, but are not limited to, furan, thiophene, pyrrole, thiadiazole (e.g., 1,2,3-thiadiazole or 1,2,4-thiadiazole), oxadiazole (e.g., 1,2,3-oxadiazole or 1,2,5-oxadiazole), oxazole, benzoxazole, isoxazole, isothiazole, pyrazole, thiazole, benzthiazole, triazole (e.g., 1,2,4-triazole or 1,2,3-triazole).
  • heteroaryls may be unsubstituted or substituted. Subsituted heteroaryls can have, for example, 1, 2, 3, 4, 5, or 6 subsitutents.
  • heterocyclic or “heterocyclyl” is meant an optionally substituted non-aromatic, partially unsaturated or fully saturated, 3- to 10-membered ring system, which includes single rings of 3 to 8 atoms in size, and polycyclic ring systems (e.g., bi- and tri-cyclic ring systems) which may include an aryl (e.g., phenyl or naphthyl) or heteroaryl group that is fused to a non-aromatic ring (e.g., cycloalkyl, cycloalkenyl, or heterocyclyl), where the ring system contains at least one heterotom.
  • polycyclic ring systems e.g., bi- and tri-cyclic ring systems
  • aryl e.g., phenyl or naphthyl
  • heteroaryl group e.g., cycloalkyl, cycloalkenyl, or heterocyclyl
  • Heterocyclic rings include those having from one to three heteroatoms independently selected from oxygen, sulfur, and nitrogen, in which the nitrogen and sulfur heteroatoms may optionally be oxidized and the nitrogen heteroatom may optionally be quaternized or substituted.
  • the term heterocylic refers to a non-aromatic 5-, 6-, or 7- membered monocyclic ring wherein at least one ring atom is a heteroatom selected from O, S, and N (wherein the nitrogen and sulfur heteroatoms may be optionally oxidized), and the remaining ring atoms are carbon, the radical being joined to the rest of the molecule via any of the ring atoms.
  • heterocycle is polycyclic
  • the constituent rings may be fused together, form a spirocyclic structure, or the polycyclic heterocycle may be a bridged heterocycle (e.g., quinuclidyl or .
  • exemplary heterocyclics include, but are not limited to, aziridinyl, azetindinyl, 1,3-diazatidinyl, pyrrolidinyl, piperidinyl, piperazinyl, thiranyl, thietanyl, tetrahydrothiophenyl, dithiolanyl, tetrahydrothiopyranyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, pyranonyl, 3,4-dihydro-2H-pyranyl, chromenyl, 2H-chromen-2-onyl, chromanyl, dioxanyl (e.g.,
  • ketone or "acyl” is meant a group having the structure -COR', where R' is selected from H, optionally substituted C 1-6 alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. When R' is not H, R may be unsubstituted or substituted with, for example, 1, 2, 3, 4, 5, or 6 substituents.
  • nitro is meant a group having the structure -NO 2 .
  • a "pharmaceutically acceptable excipient” as used herein refers any ingredient other than the compounds described herein (for example, a vehicle capable of suspending or dissolving the active compound) and having the properties of being nontoxic and non-inflammatory in a patient.
  • Excipients may include, for example: antiadherents, antioxidants, binders, coatings, compression aids, disintegrants, dyes (colors), emollients, emulsifiers, fillers (diluents), film formers or coatings, flavors, fragrances, glidants (flow enhancers), lubricants, preservatives, printing inks, sorbents, suspensing or dispersing agents, sweeteners, or waters of hydration.
  • excipients include, but are not limited to: butylated hydroxytoluene (BHT), calcium carbonate, calcium phosphate (dibasic), calcium stearate, croscarmellose, crosslinked polyvinyl pyrrolidone, citric acid, crospovidone, cysteine, ethylcellulose, gelatin, hydroxypropyl cellulose, hydroxypropyl methylcellulose, lactose, magnesium stearate, maltitol, mannitol, methionine, methylcellulose, methyl paraben, microcrystalline cellulose, polyethylene glycol, polyvinyl pyrrolidone, povidone, pregelatinized starch, propyl paraben, retinyl palmitate, shellac, silicon dioxide, sodium carboxymethyl cellulose, sodium citrate, sodium starch glycolate, sorbitol, starch (corn), stearic acid, stearic acid, sucrose, talc, titanium dioxide, vitamin A, B
  • pharmaceutically acceptable salt represents those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and animals without undue toxicity, irritation, allergic response and the like and are commensurate with a reasonable benefit/risk ratio.
  • Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66: 1-19.
  • the salts can be prepared in situ during the final isolation and purification of the compounds of the invention or separately by reacting the free base group with a suitable organic acid.
  • Representative acid addition salts include acetate, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphersulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptonate, glycerophosphate, hemisulfate, heptonate, hexanoate, hydrobromide, hydrochloride, hydroiodide, 2-hydroxy- ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate,
  • alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium and the like, as well as nontoxic ammonium, quaternary ammonium, and amine cations, including, but not limited to ammonium, tetramethylammonium, tetraethyl ammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine and the like.
  • solvates refers to compounds that retain non-covalent associations to residual solvent molecules in the solid state.
  • solvates may be prepared by crystallization, recrystallization, or precipitation from a solution that includes organic solvents, water, or a mixture thereof.
  • Solvates include, but are not limited to, compounds that include solvent molecules in the crystal lattice following recrystallization.
  • the molecular stoichiometry of solvation can vary from, for example, 1 :1 solventxompound to 10:1 solventxompound. These ratios can include a mixture of associated solvent molecules.
  • water for example, mono-, di-, and tri-hydrates
  • ⁇ MP N- methylpyrrolidinonc
  • DMSO dimethyl sulfoxide
  • DMAC N,N'-dimethylacetamide
  • DMEU
  • compositions a composition containing a compound of the invention, formulated with a pharmaceutically acceptable excipient, and manufactured or sold with the approval of a governmental regulatory agency as part of a therapeutic regimen for the treatment of disease in a mammal. Excipients consisting of DMSO are specifically excluded.
  • Pharmaceutical compositions can be formulated, for example, for oral administration in unit dosage form (e.g., a tablet, capsule, caplet, gelcap, or syrup); for topical administration (e.g., as a cream, gel, lotion, or ointment); for intravenous administration (e.g., as a sterile solution free of particulate emboli and in a solvent system suitable for intravenous use); or any other formulation described herein.
  • stereoisomer is meant a diastereomer, enantiomer, or epimer of a compound.
  • a chiral center in a compound may have the ⁇ -configuration or the ⁇ -configuration.
  • Enantiomers may also be described by the direction in which they rotate polarized light (i.e., (+) or (-)).
  • Diastereomers of a compound include stereoisomers in which some, but not all, of the chiral centers have the opposite configuration as well as those compounds in which substituents are differently oriented in space (for example, trans versus cis).
  • a substituted group may have, for example, 1, 2, 3, 4, 5, 6, 7, 8, or 9 substituents.
  • each hydrogen in a group may be replaced by a substituent group (e.g., perhaloalkyl groups such as -CF 3 or -CF 2 CF 3 or perhaloaryls such as -C 6 F 5 ).
  • a substitutent group may itself be further substituted by replacing a hydrogen of said substituent group with another substituent group such as those described herein.
  • Substituents may be further substituted with, for example, 1, 2, 3, 4, 5, or 6 substituents as defined herein.
  • a lower C 1-6 alkyl or an aryl substituent group e.g., heteroaryl, phenyl, or naphthyl
  • heterocyclic compounds of the invention include, for example, compounds of Formulas (I)- (VIII), or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof, and are shown to inhibit TNF- ⁇ induced necroptosis in FADD-deficient variant of human Jurkat T cells. Still other useful necrostatins include Compounds (l)-(45).
  • Compounds of the invention can be synthesized according to methods known in the art or by the methods provided in the examples below. Pharmaceutical compositions including the compounds of the invention are also described. The invention also features kits and methods of treatment featuring the compounds and compositions of the invention.
  • each X H i and X H2 is selected, independently, from O, S, or NR H9 ;
  • each Z H1 and Z H2 is selected, independently, from a single bond, O, S, or NRH ⁇ ;
  • each R H9 , R H io, RHII, RHI2, RHI3, RHI4, RHIS> RHI6, and R H17 is selected, independently from H, optionally substituted C 1-6 alkyl, optionally substituted C 3-I o cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, or optionally substituted heteroaryl;
  • n is an integer between 0-6; and o is 0 or 1 ; or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.
  • Z H1 is selected from a single bond or S
  • Z H2 is selected from a single bond or NR H11 ;
  • X H2 is O or S; or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.
  • the compound has a structure according to the following formula:
  • R H3 is H
  • R H4 is unsubstituted phenyl or phenyl substituted with 1, 2, or 3 substituents selected from methoxy, ethoxy, methyl, isopropyl, chloro, or fluoro
  • R H5 is CN
  • R H6 and R m is H
  • R m o is H
  • X H i is O
  • Y H1 is NH
  • Z H2 -R H17 is not OCH 3 or NH-R H17 , where R H17 is H, unsubstituted 2-thiazolyl, unsubstituted phenyl, 4-methoxyphenyl, A- fluorophenyl, or 2,4,6-trimelhylphenyl.
  • Compounds of Formula (I) can also be used as described herein (e.g., in pharmaceutical compositions, as inhibitors of necroptosis, in methods of treatment, and in kits).
  • Exemplary compounds useful in the methods, compositions, and kits of the invention include but are not limited to those shown in Table 1.
  • Other compounds of Formula 1 are shown in Table 2.
  • Formulas (I), (I -A), (I-B), or (I-C) do not include any of Compounds (1)-(12).
  • G A1 is absent or -(CR A9 R A10 ) m -;
  • G A2 is absent or -(CR AI 1 R A12 X 1 -; each R A8 and R A13 is selected, independently, from H, optionally substituted C 1-6 alkyl, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, -COR A i 4 , -CO 2 R A i4, or -CONRAMRAIS; each R A9 , R AI O , R A ⁇ , and R A12 is selected, independently, from H, halogen, optionally substituted C 1-6 alkyl, optionally substituted C 2-6 alkenyl, optionally substituted C 2-6 alkynyl, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; each R A7 , R A14 and R A15 is selected, independently, from H, optionally substituted C] -6 alkyl
  • R A] and R A4 when R A] and R A4 combine to form a carbon-carbon double bond, R A2 is H 5 R A3 is CH 3 , and R A6 is CO 2 H, R A5 is not CH 2 (2-chlorophenyl).
  • each R A1 , R A3 , R A4 , and R A7 is selected, independently, from H, optionally substituted C 1-6 alkyl, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or R A1 and R A4 combine to form a carbon-carbon double bond;
  • G A 2 is absent or is -(CR A11 R A12 ) n -;
  • X A3 is absent or is O, S, or NR A8 ;
  • each R A11 , R A12 , and R A8 is selected, independently, from H or optionally substituted C 1-6 alkyl; and n is 1 or 2; or according to Formula (H-B)
  • G A2 -X A3 -R A7 is not NHC 6 H 5 , NH(P-C 6 H 4 F), NH(p- C 6 H 4 OH), NH(p-C 6 H 4 OMe), NH(3-OH-4-Cl-C 6 H 4 ), -CH 2 (O- ⁇ -C 6 H 4 Me), - CH 2 (4-ethylpiperazinyl), -CH 2 S(2- ⁇ henyltetrazolyl), -CH 2 S(4-chlorophenyl), - CH 2 S(2-benzothiazolyl), -CH 2 S(2-(N-methylimidazolyl)), -CH 2 S(4,6- dimethylquinazolin
  • each X A3 -J ⁇ A7 optionally substituted C 1-6 alkyl, optionally substituted C 2-6 alkenyl, optionally substituted C 2-6 alkynyl, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or R A1 and R A4 combine to form a carbon-carbon double bond; each X A3 is, independently, absent, -O-, or -NR A8 -, each R A8 is selected, independently, from H, optionally substituted C 1-6 alkyl, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, -COR A14 , -CO 2 R A i 4 , or -CONR A14 R A15 ; and each R A7 , R A14 and R A15 is selected, independently, from H, optionally substituted C 1-6 al
  • R A6 is not 4- chlorophenyl, 4-methoxyphenyl. or 4-(NHCO 2 t Bu)phenyl.
  • R A i is H
  • R A4 is H or CO 2 Et
  • R A2 is unsubstituted phenyl
  • R A1 is H
  • R A2 is 4-chlorophenyl
  • R A6 is not CO 2 Et.
  • Scheme 2A shows a method that can be used to prepare pyrazole compounds of Formula (II). Terminal alkynes can be reacted with trimethylsilyldiazomethane (TMS-diazomethane) to afford compounds of
  • R A] and R A4 combine to form a carbon-carbon double bond and R' can be, for example, optionally substituted aryl or optionally substituted heteroaryl.
  • Scheme 2B shows the preparation of Compound (13) using the method in Scheme 2A in which the aniline -NH 2 group is protected prior to the reaction with TMS-diazomethane.
  • Scheme 3A depicts another method that can be used to synthesize pyrazoline compounds of Formula (II) according to methods described in J. Chem. Soc. 4686-90 (1952) and J. Med. Chem. 2127-2137 (2006).
  • substituted acroleins e.g., R' can be optionally substituted aryl or optionally substituted heteroaryl
  • Step (a) ethanolic hydrazine
  • the pyrazoline can then be treated with an electrophilic compound having a suitable leaving group (e.g., alkyl halides, acid cholorides. or acid anhydrides) and an optional chemical promotoer to afford N-substituted pyrazolines.
  • Scheme 3B shows a method that can be used to prepare Compound (14) where an acid chloride can be used in Step (b) as shown.
  • Scheme 5A depicts a method by which tetrazole compounds of Formula
  • (II) can be prepared using methods described in WO20051 15147 and in J. Med. Chem., 4686-90 (1952).
  • a tetrazole compound that includes a carboxylic acid group can be activated (e.g., treatment with PCl 5 as in Step (a)) and subsequently treated with a nucleophile R" as in Step (b).
  • Scheme 5B shows that 5-Phenyl-4,5-dihydro-lH-pyrazole can be used as the nucleophile in step (b') to afford Compound (16).
  • Compounds of Formula (II) can also be used as described herein (e.g., in pharmaceutical compositions, as inhibitors of necroptosis, in methods of treatment, and in kits). Additional exemplary compounds useful in, for example, the methods, compositions, and kits of the invention, include but are not limited to those shown in Table 3. Other compounds of Formula (II) are shown in Table 4. In some embodiments, Formula (11), (H-A), and (II-B) do not include any of compounds (13)-(26). Table 3
  • R B2 is ethyl, ethenyl, or ethynyl and each R B9 , R B10 , R BI I , and R B12 is selected, independently, from H and halogen, or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.
  • R B1 is H.
  • R B1 is as described in Formula (III)
  • R B2 is ethyl, ethenyl, or ethynyl and each R B9 , R B ⁇ O> R B ⁇
  • R B12 is selected, independently, from H and halogen, or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.
  • R BI is H.
  • R B] is not H when R B5 , R B6; R B7> R BS , R B IO> and R B1 ] are each H, at least one of R B9 or R B ] 2 is fluoro, R B2 is ethynyl, and when R B3 and R B4 combine to form -CH 2 CH 2 -.
  • R B1 is not H when R B6 , R B7 , R B8 , RB 10 , and R B] 1 are H and one or two of R B6 , R B8 , R BIO , and R B]2 is halogen, nitro, or methyl.
  • Scheme 6A depicts a method by which compounds of Formula (III) can be prepared.
  • a ketone derivative can be treated with an anionic carbon nucleophile (e.g., lithium trimethylsilylacetylide formed in step (a)).
  • the resulting alkoxide can be trapped using a protic quench or by the addition of an electrophilic reagent.
  • the trimethylsilyl group can be deprotected using basic conditions.
  • the alkyne group can be further manipulated (e.g., subjected to hydrogenation conditions to afford the corresponding alkene or alkyl group or treated with a metal catalyst/and organic electrophile in cross- coupling reactions).
  • Scheme 6B shows Compound (27), which can be prepared using these conditions.
  • Compounds of Formula (III) e.g., (III-A) and (HI-B) and compound
  • Rc9 > Rcio > R-cib an d Rc ⁇ is selected, independently, from H, optionally substituted C ]-6 alkyl, optionally substituted C 3-1O cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
  • Y is, independently, a single bond, (CRc 8 Rc ⁇ n , O, S, or NRc 10 ; Z is a single bond, O, S, or NR C i 0 ; or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.
  • R C4 is H
  • R 05 and R C6 combine to form unsubstituted cyclopentyl
  • Rc 3 is not -CH 2 -Rc 7 , where Rc 7 is unsubstituted phenyl, unsubstituted naphthyl, unsubstituted 8-quinolyl, unsubstituted 2- oxoquinolyl, or phenyl having 1 or 2 substituents selected from F, OMe, Me, CN, or Cl.
  • Scheme 7A depicts a method by which compounds of Formula (IV) (e.g., compounds of Formula (IV-A)) can be prepared.
  • a heterocyclic derivative can be deprotonated using a base such as NaH and subsequently treated with an electrophile (e.g., an alkyl halide such as benzyl bromide, an acid chloride, or an acid anhydride) to afford a compound of Formula (IV) such as Compound (48) shown in Scheme 7B.
  • an electrophile e.g., an alkyl halide such as benzyl bromide, an acid chloride, or an acid anhydride
  • Compounds of Formula (IV) can also be used as described herein (e.g., in pharmaceutical compositions, as inhibitors of necroptosis, in methods of treatment, and in kits). Additional exemplary compounds useful in, for example, the methods, compositions, and kits of the invention, include but are not limited to those shown in Table 7. In some embodiments, Formula (IV) does not include any of Compounds (48)- (57).
  • each Xm and X D2 is selected, independently, from O, S, NR D5 , or
  • A is selected from optionally substituted aryl or optionally substituted heteroaryl
  • G D is selected from H, optionally substituted C 1-6 alkyl, optionally substituted C 3-I0 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, OR D9 , or NR D9 R D10 ; each R D i, R D2 , R D3 , R D4 , R D6 , R D7> is selected, independently, from H, halogen, CN, NC, N 3 , NO 2 , OR 0n , SR 011 , NR D] 1 R D12 , -COR 013 , -CO 2 R 013 , -CONR D] 3 R D]4 , optionally substituted Ci -6 alkyl, optionally substituted C 3-]0 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or R D1 and R D4 , or R D1 and R D5 , or
  • A is phenyl having O, 1, 2, 3, or 4 additional substituents;
  • R D2 and R 03 are selected, independently from H, halogen, CN, NC, N 3 , NO 2 , -COR 013 , -CO 2 R 013 , -CONR 013 R 014 , optionally substituted C 1-6 alkyl, optionally substituted C 3-)0 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; each R 05 , R D9 , R 01 o > R DI3> ar *d R DH is selected, independently, from H, optionally substituted C 1-6 alkyl, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or R 09 and R 010 combine to form a heterocyclyl; or by Formula (V-B)
  • each R D2 , R 03 , RD ⁇ > RDI S> RDI 9> an d R D 20, is selected, independently from H, halogen, CN, NC, N 3 , NO 2 , -COR 013 , -CO 2 R 013 , -CONR 013 R 014 , optionally substituted C 1-6 alkyl, optionally substituted aryl, or optionally substituted heteroaryl; and each R 09 and R 010 is selected, independently, from H, optionally substituted Ci -6 alkyl, optionally substituted C 3-I0 cycloalkyl, or optionally substituted aryl, or R 09 and R O i 0 combine to form a heterocyclyl; or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.
  • R 02 and R 03 are H
  • X 01 is NH
  • X 02 is S
  • Y D2 is -(SO 2 )-
  • G 01 is -N(Et) 2
  • A is phenyl having no additional substituents, Y D i and Y 02 are not para to each other.
  • Compounds of Formula (V) can be prepared, for example, by treating an aryl or heteroaryl compound that has two electrophilic groups successively with nucleophilic reagents to afford the desired compound.
  • nucleophilic reagents for example, as shown in Scheme 8 and using procedures adapted from Heterocyclic Communications, 12(6): 453-456 (2006) and Organic Synthesis, Collective Vol. 6, page 818, the difunctional benzene derivative 4-CO 2 Hphenylsulfonyl chloride can be treated with a nucleophile such as diethylamine to afford the corresponding sulfonamide.
  • step (c) can then be condensed with a carbonyl-containing compound to afford compounds of Formula (V) such as Compound (58).
  • Compounds of Formula (V) (e.g., (V-A) and (V-B) and compound (34)), or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof, can also be used as described herein (e.g., in pharmaceutical compositions, as inhibitors of necroptosis, in methods of treatment, and in kits).
  • Formulas (V), (V-A), and (V-B) do not include Compounds (58).
  • each X E1 and X E3 is selected, independently, from N or CR E4 ; each X E4 and X E5 is selected, independently, from O, S, or NR E5 ;
  • X E2 is selected from O, S, or N; each Z E1 , Z E2 , and Z E3 is selected, independently, from a single bond, -(CR E6 R E7 ) n -, -C(O)-, -S(O)-, or -S(O) 2 -, or Z E1 -R E1 and Z E2 -R E2 combine to form a double bond; each R E] , R E2 , R E3 , R E4 , R E5 , R E6 , and R E7 is selected, independently, from H, optionally substituted C ]-6 alkyl, optionally substituted C 2-6 alkenyl, optionally substituted C 2-6 alkynyl, optionally substituted C 3-1O cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; p is 0 or 1 ; and n is an integer between 1-6; and where when X
  • each R E1 , R E2 , RE 3 , RE4, RES, RE 6> an d RE 7 is selected, independently, from H, optionally substituted Cj -6 alkyl, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl
  • R E3 is selected from substituted C 1-6 alkyl, optionally substituted C 2-6 alkenyl, optionally substituted C 2-6 alkynyl, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.
  • X E1 is CH
  • -Z E1 -R E I is -CH 2 (indol-3-yl)
  • X E4 and Xg 5 are O
  • X E2 -Z E2 -R E2 is NH
  • X E3 -Z E3 -R E3 is not -NCH 2 (P-ClC 6 H 4 ) or -NCH 2 CH 2 O(p-FC 6 H 4 ).
  • the R E3 group can be unsubstituted.
  • a substituted R E3 group includes 1, 2, 3, 4, or 5 substituents selected from, for example, C 1 -6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, azido(-N 3 ), alkoxy (-OR'), amido (-NR 5 C(O)R “ ' or -C(O)NRR'), amino (-NRR'), carbamoyl (-OC(O)NR 5 R" or - NRC(O)OR' ), hydroxy (-OH), or isocyano (-NC), where each R or R' is selected, independently, from H, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl.
  • the substituted R E3 group includes 1, 2, 3, or 4 substituents that are
  • each Z E2 and Z E3 is selected, independently, from a single bond, -(CR E6 R E7 ) n -, -C(O)-, or R E
  • each R EI , R E2 , R E3 , and R E4 is selected, independently, from H, optionally substituted C] -6 alkyl, optionally substituted C 2-6 alkenyl, optionally substituted C 2-6 alkynyl, optionally substituted C 3-J0 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
  • each R E6 and R E7 is selected, independently, from H or optionally substituted C 1-6 alkyl; and n is an integer between 1-6; or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.
  • each RE 1 , R E 2 ; RE 3> and R E4 is selected, independently, from H, optionally substituted C 1-6 alkyl, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.
  • R E3 is selected from substituted C 1-6 alkyl, optionally substituted C 2-6 alkenyl, optionally substituted C 2-6 alkynyl, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.
  • R E1 and R E4 are H, Z E2 and Z E3 are each CH 2 , and R E2 is unsubstituted 3-indolyl, R E3 is not 4- chlorophenyl.
  • X E2 is O or N; each Z E2 and Z E3 is selected, independently, from a single bond or -(CR E6 R E7 ) n -; each R E2 and R E3 is, independently, H, optionally substituted C !
  • each R 3 and R 4 is, independently, H, halogen, or optionally substituted C 1-6 alkyl; each R 3 , R 6 , R 7 , R 8 , and R 9 is selected, independently, from H, halogen,
  • R 10 is selected from H, halogen, CN, NO 2 , OR 13 , NR 13 R 14 , COR 15 , CO 2 R 15 , optionally substituted C 1-6 alkyl, or optionally substituted aryl;
  • R 10 is selected from H, halogen, CN, NO 2 , OR 13 , NR 13 R 14 , COR 15 , CO 2 R 15 , optionally substituted C 1-6 alkyl, optionally substituted aryl, optionally substituted alkenyl, or optionally substituted alkynyl;
  • each R 13 and R 14 is selected, independently, from H, COR 16 , CO 2 R 16 , optionally substituted C 1-6 alkyl, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
  • each R 11 , R 12 , R 15 , and R 16 is selected, independently, from H, optionally substituted C 1-6 alky
  • R E3 is selected from substituted C 1-6 alkyl, optionally substituted C 3-10 cycloalkyl, optionally substituted C 2-6 alkenyl, optionally substituted C 2-6 alkynyl, optionally substituted aryl, optionally substituted heterocyclyl, or optionally substituted heteroaryl.
  • Select compounds of Formula (VI-C) can also be described by Formula
  • X E5 is O or S
  • each R 3 , R 4 , and R 10 is, independently, H or optionally substituted C ] -6 alkyl;
  • R 9 is H, halogen, CN, NO 2 , OR 13 , NR 13 R 14 , COR 15 , CO 2 R 15 , or optionally substituted Ci -6 alkyl; each R 13 and R 14 is selected, independently, from H, COR 16 , CO 2 R 16 , optionally substituted C 1-6 alkyl, optionally substituted C 3-J0 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; and each R 11 , R 12 , R 15 , and R 16 is selected, independently, from H, optionally substituted C 1-6 alkyl, optionally substituted C 3-1O cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; and where n is 1 or 2; or any pharmaceutically acceptable salt or solvate thereof, or stereoisomer thereof.
  • the compound has a structure according to the following formula:
  • the sp -hybridized carbon to which G is attached can have the (R)- or the ( ⁇ -configuration.
  • compounds of the invention include
  • n 1 and R 3 and R 4 are each H.
  • R 10 is H or CH 3 .
  • R 9 is H, halogen, optionally substituted C 1-6 alkyl, OH, or -O- (optionally substituted C 1-6 alkyl).
  • -Z E3 -R E3 is optionally substituted benzyl. In one embodiment, -Z E3 -R E3 is unsubstituted benzyl. In another embodiment, -Z E3 -R E3 is benzyl having 1, 2, 3, 4, or 5 substituents.
  • -Z E3 -R E3 is CH 2 -(p-XC 6 H 4 ), where X is halogen.
  • X is F or Cl.
  • each R or R' is selected, independently, from H, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, as described herein.
  • Formula (VI) (e.g., compounds of Formulas (VI- A), (VI-B), (VI-C), or (VI-D)) does not include any of the compounds or formulas disclosed in U.S. Patent Nos. 6,756,394 and 7,253,201, in U.S. Patent Publication No. 20050119260, and in pending U.S. Application Nos. 12/077,320 and 12/086,792, each of which is hereby incorporated by reference.
  • Compounds of Formula (VI) (e.g., (VI-A)-(VI-D) and compound (59)), or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof, can also be used as described herein (e.g., in pharmaceutical compositions, as inhibitors of necroptosis, in methods of treatment, and in kits). In some embodiments, Formula (VI) does not include compound (59).
  • CN NC, N 3 , NO 2 , ORpi 2 , SR F12 , NR F12 R F13 , -COR F12 , -CO 2 F12 , -CONR FI2 R F13 , optionally substituted C 1-6 alkyl, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; and where n is an integer between 1-6; or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.
  • R F1 is selected from H, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
  • R F2 and R F4 are each H, or R F2 and R F4 combine to form a carbon-carbon double bond;
  • Scheme 10 provides a method by which compounds of Formula (VII) such as Compound (60) can be prepared.
  • a nucleophilic compound such as indoline can be treated with an electrophile (e.g., a compound containing a carboxylic acid) in the presence of an optional promoter such as DEAD/PPh 3 to afford the requisite compound.
  • an electrophile e.g., a compound containing a carboxylic acid
  • an optional promoter such as DEAD/PPh 3
  • Formulas (VII) e.g., (VII-A) and compound (60)
  • any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof can also be used as described herein (e.g., in pharmaceutical compositions, as inhibitors of necroptosis, in methods of treatment, and in kits).
  • Formulas (VII) and (VII-A) do not include compounds (60) or (61).
  • X 0 is selected from -O-, -N-, or -(CR G9 R G I O )II-;
  • X G2 and X 03 are selected, independently, from N or CR G1 ⁇ ; each RQI , RG2> RG3> RG4> RGS? RG6J RG7> RGS? R-G95 RGIO> an d RGI I is selected, independently, from H, optionally substituted C 1-6 alkyl, optionally substituted C 3- ] O cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or R G i and R 02 , or R 03 and R G4 , or R G5 and R 06 , or R 07 and R 08 combine to form an optionally substituted cycloalkyl or heterocyclyl; and n is 1 or 2; or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.
  • each R 01 , R G2 , R 05 , and R 06 is selected, independently, from H, optionally substituted C 1-6 alkyl, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or R G j and RG 2 , or R 05 and RQ 6 combine to form an optionally substituted cycloalkyl or heterocyclyl, or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.
  • Formula (VIII-A) can be prepared are known in the art.
  • Compound (62) shown in Scheme 12 can be prepared according to methods described in Synthesis, pages 771-783 (2002).
  • Formulas (VIII) e.g., (VIII-A) and compound (62)
  • any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof can also be used as described herein (e.g., in pharmaceutical compositions, as inhibitors of necroptosis, in methods of treatment, and in kits).
  • Formulas (VIII) and (VIII-A) do not include compound (62).
  • the necrostatins described herein can be formulated into pharmaceutical compositions for administration to human subjects in a biologically compatible form suitable for administration in vivo.
  • the present invention provides a pharmaceutical composition comprising a compound of the invention in admixture with a pharmaceutically acceptable excipient.
  • Conventional procedures and ingredients for the selection and preparation of suitable formulations are described, for example, in Remington's Pharmaceutical Sciences (2003 - 20 th edition) and in The United States Pharmacopeia: The National Formulary (USP 24 NF 19), published in 1999.
  • the compounds may be used in the form of the free base, in the form of salts, solvates, and as prodrugs. All forms are within the scope of the invention.
  • the described compounds or salts, solvates, or prodrugs thereof may be administered to a patient in a variety of forms depending on the selected route of administration, as will be understood by those skilled in the art.
  • the compounds of the invention may be administered, for example, by oral, parenteral, buccal, sublingual, nasal, rectal, patch, pump, or transdermal administration and the pharmaceutical compositions formulated accordingly.
  • Parenteral administration includes intravenous, intraperitoneal, subcutaneous, intramuscular, transepithelial, nasal, intrapulmonary, intrathecal, rectal, and topical modes of administration. Parenteral administration may be by continuous infusion over a selected period of time.
  • Pharmaceutically acceptable excipients may include, for example: antiadherents, antioxidants, binders, coatings, compression aids, disintegrants, dyes (colors), emollients, emulsifiers, fillers (diluents), film formers or coatings, flavors, fragrances, glidants (flow enhancers), lubricants, preservatives, printing inks, sorbents, suspensing or dispersing agents, sweeteners, or waters of hydration.
  • excipients include, but are not limited to: butylated hydroxytoluene (BHT), calcium carbonate, calcium phosphate (dibasic), calcium stearate, croscarmellose, crosslinked polyvinyl pyrrolidone, citric acid, crospovidonc, cysteine, ethylcellulose, gelatin, hydroxypropyl cellulose, hydroxypropyl methylcellulose, lactose, magnesium stearate, maltitol, mannitol, methionine, methylcellulose, methyl paraben, microcrystalline cellulose, polyethylene glycol, polyvinyl pyrrolidone, povidone, pregelatinized starch, propyl paraben, rctinyl palmitate, shellac, silicon dioxide, sodium carboxymethyl cellulose, sodium citrate, sodium starch glycolate, sorbitol, starch (corn), stearic acid, stearic acid, sucrose, talc, titanium dioxide,
  • any of the compounds described herein may be orally administered, for example, with an inert diluent or with an assimilable edible carrier, or it may be enclosed in hard or soft shell gelatin capsules, or it may be compressed into tablets, or it may be incorporated directly with the food of the diet.
  • a compound of the invention may be incorporated with an excipient and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like.
  • a compound may also be administered parenterally.
  • the pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases the form must be sterile and must be fluid to the extent that may be easily administered via syringe.
  • compositions for nasal administration may conveniently be formulated as aerosols, drops, gels, and powders.
  • Aerosol formulations typically include a solution or fine suspension of the active substance in a physiologically acceptable aqueous or non-aqueous solvent and are usually presented in single or multidose quantities in sterile form in a sealed container, which can take the form of a cartridge or refill for use with an atomizing device.
  • the sealed container may be a unitary dispensing device, such as a single dose nasal inhaler or an aerosol dispenser fitted with a metering valve which is intended for disposal after use.
  • the dosage form comprises an aerosol dispenser
  • a propellant which can be a compressed gas, such as compressed air or an organic propellant, such as fluorochlorohydrocarbon.
  • the aerosol dosage forms can also take the form of a pump-atomizer.
  • compositions suitable for buccal or sublingual administration include tablets, lozenges, and pastilles, where the active ingredient is formulated with a carrier, such as sugar, acacia, tragacanth, or gelatin and glycerine.
  • Compositions for rectal administration are conveniently in the form of suppositories containing a conventional suppository base, such as cocoa butter.
  • the compounds of the invention may be administered to an animal alone or in combination with pharmaceutically acceptable carriers, as noted above, the proportion of which is determined by the solubility and chemical nature of the compound, chosen route of administration, and standard pharmaceutical practice.
  • the amount of active ingredient e.g., a compound of Formulas (I)- (VIII) or any of compounds (l)-(7), (13)-(26), (27)-(33), (48)-(57), or (58)- (70)) in the compositions of the invention can be varied.
  • active ingredient e.g., a compound of Formulas (I)- (VIII) or any of compounds (l)-(7), (13)-(26), (27)-(33), (48)-(57), or (58)- (70)
  • dosage levels of between 0.1 ⁇ g/kg to 100 mg/kg of body weight are administered daily as a single dose or divided into multiple doses.
  • the general dosage range is between 250 ⁇ g/kg to 5.0 mg/kg of body weight per day. Wide variations in the needed dosage are to be expected in view of the differing efficiencies of the various routes of administration. For instance, oral administration generally would be expected to require higher dosage levels than administration by intravenous injection. Variations in these dosage levels can be adjusted using standard empirical routines for optimization, which are well known in the art. In general, the precise therapeutically effective dosage will be determined by the attending physician in consideration of the above identified factors.
  • the compounds disclosed herein can be used to treat disorders where necroptosis is likely to play a substantial role (e.g., cerebral ischemia, traumatic brain injury, a neurodegenerative disease of the central or peripheral nervous system, the result of retinal neuronal cell death, the result of cell death of cardiac muscle, the result of cell death of cells of the immune system; stroke, liver disease, pancreatic disease, the result of cell death associated with renal failure; heart, mesenteric, retinal, hepatic or brain ischemic injury, ischemic injury during organ storage, head trauma, septic shock, coronary heart disease, cardiomyopathy, myocardial infarction, bone avascular necrosis, sickle cell disease, muscle wasting, gastrointestinal disease, tuberculosis, diabetes, alteration of blood vessels, muscular dys
  • the compounds identified to decrease necrosis or necroptosis may be structurally modified and subsequently used to decrease necrosis or necroptosis, or to treat a subject with a condition in which necrosis or necroptosis occurs.
  • the methods used to generate structural derivatives of the small molecules that decrease necrosis or necroptosis are readily known to those skilled in the fields of organic and medicinal chemistry.
  • Therapy according to the invention may be performed alone or in conjunction with another therapy, for example in combination with apoptosis inhibitors, and may be provided at home, the doctor's office, a clinic, a hospital's outpatient department, or a hospital.
  • Treatment generally begins at a hospital so that the doctor can observe the therapy's effects closely and make any adjustments that are needed.
  • the duration of the therapy depends on the age and condition of the patient, as well as how the patient responds to the treatment. Additionally, a person having a greater risk of developing a condition may receive prophylactic treatment to inhibit or delay symptoms of the disease.
  • the compounds and methods of the invention can be used to treat any of the following disorders where necroptosis is likely to play a substantial role: a neurodegenerative disease of the central or peripheral nervous system, the result of retinal neuronal cell death, the result of cell death of cardiac muscle, the result of cell death of cells of the immune system; stroke, liver disease, pancreatic disease, the result of cell death associated with renal failure; heart, mesenteric, retinal, hepatic or brain ischemic injury, ischemic injury during organ storage, head trauma, septic shock, coronary heart disease, cardiomyopathy, myocardial infarction, bone avascular necrosis, sickle cell disease, muscle wasting, gastrointestinal disease, tuberculosis, diabetes, alteration of blood vessels, muscular dystrophy, graft- versus-host disease, viral infection, Crohn's disease, ulcerative colitis, asthma, and any condition in which alteration in cell proliferation, differentiation or intracellular signaling is a causative factor.
  • Conditions in which alteration in cell proliferation, differentiation or intracellular signaling is a causative factor include cancer and infection, e.g., by viruses (e.g., acute, latent and persistent), bacteria, fungi, or other microbes.
  • viruses e.g., acute, latent and persistent
  • exemplary viruses are human immunodeficiency virus (HIV), Epstein- Barr virus (EBV), cytomegalovirus (CMV)5 human herpesviruses (HHV), herpes simplex viruses (HSV), human T-CeIl leukemia viruses (HTL V)5 Varicella-Zoster virus (VZV), measles virus, papovaviruses (JC and BK), hepatitis viruses, adenovirus, parvoviruses, and human papillomaviruses.
  • viruses are human immunodeficiency virus (HIV), Epstein- Barr virus (EBV), cytomegalovirus (CMV)5 human herpesviruses
  • Exemplary bacteria include, but are not limited to Campylobacter jejuni, Enterobacter species, Enterococcus faecium, Enterococcus faecalis, Escherichia coli (e.g., E. coli O157:H7), Group A streptococci, Haemophilus influenzae, Helicobacter pylori, listeria, Mycobacterium tuberculosis, Pseudomonas aeruginosa, S. pneumoniae, Salmonella, Shigella, Staphylococcus aureus, and Staphylococcus epidermidis.
  • Campylobacter jejuni Enterobacter species
  • Enterococcus faecium Enterococcus faecalis
  • Escherichia coli e.g., E. coli O157:H7
  • Group A streptococci Haemophilus influenzae
  • Helicobacter pylori listeria
  • Exemplary diseases caused by bacterial infection include, but are not limited to, anthrax, cholera, diphtheria, foodborne illnesses, leprosy, meningitis, peptic ulcer disease, pneumonia, sepsis, tetanus, tuberculosis, typhoid fever, and urinary tract infection.
  • Neurodegenerative Diseases Exemplary neurodegenerative diseases are Alzheimer's disease,
  • Huntington's disease Parkinson's disease, amyotrophic lateral sclerosis, HIV- associated dementia, cerebral ischemia, amyotropic lateral sclerosis, multiple sclerosis, Lewy body disease, Menke's disease, Wilson's disease, Creutzfeldt- Jakob disease, and Fahr disease.
  • Exemplary muscular dystrophies or related diseases are Becker's muscular dystrophy, Duchenne muscular dystrophy, myotonic dystrophy, limb-girdle muscular dystrophy, Landouzy-Dejerine muscular dystrophy, facioscapulohumeral muscular dystrophy (Steinert's disease), myotonia congenita, Thomsen's disease, and Pompe's disease.
  • Muscle wasting can be associated with cancer, AIDS, congestive heart failure, and chronic obstructive pulmonary disease, as well as include necrotizing myopathy of intensive care.
  • Compounds and methods of the invention can additionally be used to boost the immune system, whether or not the patient being treated has an immunocompromising condition.
  • the compounds described herein can be used in a method to strengthen the immune system during immunization, e.g., by functioning as an adjuvant, or by being combined with an adjuvant.
  • any of the compounds or pharmaceutical compositions of the invention can be used together with a set of instructions, i.e., to form a kit.
  • the kit may include instructions for use of the compounds of the invention in a screening method or as a therapy as described herein.
  • the following non-limiting examples are illustrative of the present invention.
  • EXAMPLE 1 DETERMINATION OF NECROPTOSIS INHIBITORY ACTIVITY
  • necroptosis inhibitory activity was performed using a FADD-deficient variant of human Jurkat T cells or with L929 cells treated with TNF- ⁇ as previously described (Degterev et al., Nat. Chem. Biol. 1 :1 12 (2005) and Jagtap et al., J. Med. Chem. 50: 1886 (2007)). Utilizing these conditions the cells efficiently underwent necroptosis. For EC 5O value determinations, cells were treated with 10 ng/mL of human TNF- ⁇ in the presence of increasing concentration of test compounds for 24 hours followed by ATP-based viability assessment.
  • necroptosis activity was performed using a FADD-deficient variant of human Jurkat T cells or L929 cells treated with TNF- ⁇ .
  • cells 500,000 cells/mL, 100 ⁇ L per well in a 96-well plate
  • 10 ng/mL of human TNF- ⁇ in the presence of increasing concentration of test compounds for 24 hours at 37 0 C in a humidified incubator with 5% CO 2 followed by ATP- based viability assessment.
  • Stock solutions (30 mM) in DMSO were initially prepared and then diluted with DMSO to give testing solutions, which were added to each test well. The final DMSO concentration was 0.5%.
  • EC 50 values were calculated using nonlinear regression analysis of sigmoid dose-response (variable slope) curves from plots of log[I] verses viability values.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
PCT/US2009/069483 2008-12-23 2009-12-23 Small molecule inhibitors of necroptosis Ceased WO2010075561A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
EP09835866A EP2381775A4 (en) 2008-12-23 2009-12-23 INHIBITORS OF NECROPTOSIS OF SMALL MOLECULAR SIZE
BRPI0923126-9A BRPI0923126A2 (pt) 2008-12-23 2009-12-23 Compostos inibidores de molécula pequena de necroptose, uso e composição compreendendo os mesmos e método de diminuir necroptose
CN2009801569144A CN102316735A (zh) 2008-12-23 2009-12-23 坏死性凋亡的小分子抑制剂
AU2009329879A AU2009329879A1 (en) 2008-12-23 2009-12-23 Small molecule inhibitors of necroptosis
JP2011543689A JP2012513481A (ja) 2008-12-23 2009-12-23 ネクロトーシスの小分子阻害剤
CA2772760A CA2772760A1 (en) 2008-12-23 2009-12-23 Small molecule inhibitors of necroptosis
US13/141,545 US20120122889A1 (en) 2008-12-23 2009-12-23 Small molecule inhibitors of necroptosis
US14/033,176 US9586880B2 (en) 2008-12-23 2013-09-20 Small molecule inhibitors of necroptosis
US15/427,699 US20170305824A1 (en) 2008-12-23 2017-02-08 Small molecule inhibitors of necroptosis
US16/055,898 US20190135718A1 (en) 2008-12-23 2018-08-06 Small molecule inhibitors of necroptosis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14061508P 2008-12-23 2008-12-23
US61/140,615 2008-12-23

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/141,545 A-371-Of-International US20120122889A1 (en) 2008-12-23 2009-12-23 Small molecule inhibitors of necroptosis
US14/033,176 Continuation US9586880B2 (en) 2008-12-23 2013-09-20 Small molecule inhibitors of necroptosis

Publications (1)

Publication Number Publication Date
WO2010075561A1 true WO2010075561A1 (en) 2010-07-01

Family

ID=42288162

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/069483 Ceased WO2010075561A1 (en) 2008-12-23 2009-12-23 Small molecule inhibitors of necroptosis

Country Status (9)

Country Link
US (4) US20120122889A1 (enExample)
EP (2) EP2381775A4 (enExample)
JP (2) JP2012513481A (enExample)
CN (2) CN104803986A (enExample)
AU (2) AU2009329879A1 (enExample)
BR (1) BRPI0923126A2 (enExample)
CA (1) CA2772760A1 (enExample)
HK (2) HK1212973A1 (enExample)
WO (1) WO2010075561A1 (enExample)

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8143300B2 (en) 2003-08-29 2012-03-27 President And Fellows Of Harvard College Inhibitors of cellular necrosis
US8278344B2 (en) 2007-08-15 2012-10-02 The Brigham And Women's Hospital, Inc. Heterocyclic inhibitors of necroptosis
US8569331B2 (en) 2010-11-01 2013-10-29 Arqule, Inc. Substituted benzo[f]lmidazo[1,2-d]pyrido[2,3-b][1,4]diazepine compounds
US8598156B2 (en) 2010-03-25 2013-12-03 Glaxosmithkline Llc Chemical compounds
KR101410332B1 (ko) 2012-02-29 2014-06-24 코아스템(주) 중간엽 기질세포 배양용 항산화 조성물 및 이의 용도
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
US8969347B2 (en) 2008-06-03 2015-03-03 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US9359379B2 (en) 2012-10-02 2016-06-07 Intermune, Inc. Anti-fibrotic pyridinones
WO2016101887A1 (en) * 2014-12-24 2016-06-30 National Institute Of Biological Sciences, Beijing Necrosis inhibitors
WO2016101885A1 (en) 2014-12-24 2016-06-30 National Institute Of Biological Sciences, Beijing Necrosis inhibitors
US9394285B2 (en) 2013-03-15 2016-07-19 Pfizer Inc. Indole and indazole compounds that activate AMPK
US9499521B2 (en) 2014-12-11 2016-11-22 President And Fellows Of Harvard College Inhibitors of cellular necrosis and related methods
WO2016185423A1 (en) 2015-05-19 2016-11-24 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
EP2968276A4 (en) * 2013-03-15 2017-02-15 President and Fellows of Harvard College Hybrid necroptosis inhibitors
US9586880B2 (en) 2008-12-23 2017-03-07 President And Fellows Of Harvard College Small molecule inhibitors of necroptosis
US9643977B2 (en) 2011-03-11 2017-05-09 President And Fellows Of Harvard College Necroptosis inhibitors and methods of use therefor
US9750815B2 (en) 2010-07-26 2017-09-05 Gnosis Spa Composition comprising shellac and/or a salt thereof and sodium starch glycolate
US10005739B2 (en) 2013-10-23 2018-06-26 Chugai Seiyaku Kabushiki Kaisha Quinazolinone and isoquinolinone derivative
US10233195B2 (en) 2014-04-02 2019-03-19 Intermune, Inc. Anti-fibrotic pyridinones
WO2020103859A1 (en) 2018-11-20 2020-05-28 Sironax Ltd RIP1 Inhibitors
US11168068B2 (en) 2016-07-18 2021-11-09 Janssen Pharmaceutica Nv Tau PET imaging ligands
WO2021233397A1 (en) 2020-05-20 2021-11-25 Sironax Ltd. Piperazine cyclic ureas
US11690850B2 (en) 2019-11-26 2023-07-04 Board Of Regents, The University Of Texas System Inhibitors of receptor interacting protein kinase I for the treatment of disease
US11718612B2 (en) 2019-09-06 2023-08-08 Board Of Regents, The University Of Texas System Inhibitors of receptor interacting protein kinase I for the treatment of disease
US11753381B2 (en) 2019-09-27 2023-09-12 Board Of Regents, The University Of Texas System Inhibitors of receptor interacting protein kinase I for the treatment of disease
IL275739B1 (en) * 2017-12-31 2024-06-01 Evergreen Biosciences Preparations for cryopreservation and methods of their use

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI638815B (zh) 2013-02-15 2018-10-21 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺類（一）
CN103396376B (zh) * 2013-07-31 2016-08-10 杨文茂 一种抗菌抗癌活性化合物
AR103297A1 (es) 2014-12-30 2017-05-03 Forma Therapeutics Inc Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 específica de ubiquitina
MA41291A (fr) 2014-12-30 2017-11-07 Forma Therapeutics Inc Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer
JP2018504430A (ja) 2015-02-05 2018-02-15 フォーマ セラピューティクス，インコーポレイテッド ユビキチン特異的プロテアーゼ７阻害物質としてのキナゾリノン及びアザキナゾリノン
HK1248221A1 (zh) 2015-02-05 2018-10-12 Forma Therapeutics, Inc. 异噻唑啉酮类，吡唑并嘧啶酮类和吡咯并嘧啶酮作为泛蛋白特异性蛋白酶7抑制剂
JP2018504431A (ja) 2015-02-05 2018-02-15 フォーマ セラピューティクス，インコーポレイテッド ユビキチン特異的プロテアーゼ７阻害物質としてのチエノピリミジノン
WO2016133888A1 (en) * 2015-02-16 2016-08-25 Biota Pharmaceuticals, Inc. Compounds for treating respiratory syncytial virus infections
DE102015212208A1 (de) 2015-04-24 2016-10-27 Ihp Gmbh-Innovations For High Performance Microelectronics / Leibniz-Institut Für Innovative Mikroelektronik Hochgeschwindigkeits-Germanium-PIN-Fotodiode
HK1255074A1 (zh) 2015-07-01 2019-08-02 Crinetics Pharmaceuticals, Inc. 生长抑素调节剂及其用途
IL247368A0 (en) 2016-08-18 2016-11-30 Yeda Res & Dev Diagnostic and therapeutic uses of exosomes
JP2020509009A (ja) 2017-02-27 2020-03-26 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ キナーゼ阻害剤としての複素環式アミド
WO2019023278A1 (en) 2017-07-25 2019-01-31 Crinetics Pharmaceuticals, Inc. MODULATORS OF SOMATOSTATIN AND USES THEREOF
CN109078187B (zh) * 2018-08-02 2021-04-20 中国人民解放军第四军医大学 胰腺GnIH受体功能调节剂制备治疗2型糖尿病药物的应用
WO2020044206A1 (en) 2018-08-29 2020-03-05 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors for use in the treatment cancer
AU2019382504B2 (en) * 2018-11-20 2024-11-14 Sironax Ltd Cyclic ureas
CN111978311B (zh) * 2019-05-21 2024-05-31 中国科学院上海有机化学研究所 一类细胞程序性坏死抑制剂及其制备方法和用途
US20230192662A1 (en) * 2020-05-20 2023-06-22 Sironax Ltd. Receptor-Interacting Protein 1 Inhibitors Including Piperazine Heterocyclic Amide Ureas
EP4164654A4 (en) * 2020-06-12 2024-08-21 Merck Sharp & Dohme LLC RIPK1 INHIBITORS AND METHODS OF USE
CA3182873A1 (en) * 2020-06-19 2021-12-23 Jean-Marc Daniel GARNIER Sulphonamide compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6300349B1 (en) * 1995-09-19 2001-10-09 Solomon B. Margolin Inhibition of tumor necrosis factor alpha
US20070099936A1 (en) * 2005-11-01 2007-05-03 Hiayan Bian Dihydroisoindolones As Allosteric Modulators Of Glucokinase
US20080045541A1 (en) * 2004-02-19 2008-02-21 Bayer-Healthcare Ag Dihydropyridinone Derivatives

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3577420A (en) * 1968-01-05 1971-05-04 Pfizer Certain 4-aminofuro(2,3-d)pyrimidines
BE789948A (fr) 1971-10-13 1973-04-11 Sandoz Sa Nouveaux derives du pyrazole, leur preparation et leur application comme medicaments
JPS5113156B2 (enExample) 1972-10-21 1976-04-26
US4016037A (en) 1975-10-15 1977-04-05 Ajinomoto Co., Inc. Method for producing L-amino acid
US4110536A (en) * 1977-04-18 1978-08-29 Miles Laboratories, Inc. Derivatives of 5-(indol-3-yl)hydantoin
DE2728523C2 (de) 1977-06-23 1986-02-27 Schering AG, 1000 Berlin und 4709 Bergkamen 4-Methyl-1,2,3-thiadiazol-5-carbonsäure-(cyclohexylmethyl)-amid, Mittel mit herbizider und wachstumsregulatorischer Wirkung enthaltend diese Verbindung sowie Verfahren zu seiner Herstellung
JPS5810074B2 (ja) 1979-07-18 1983-02-24 味の素株式会社 新規微生物
SG56656G (en) 1980-07-28 1987-03-27 Pfizer Hypoglycemic 5-substituted oxazolidine-2, 4-diones
US4332952A (en) 1980-07-28 1982-06-01 Pfizer Inc. Hypoglycemic 5-substituted oxazolidine-2,4-diones
EP0164247B1 (en) 1984-06-07 1989-01-11 Pfizer Limited Dihydropyridines
JPS6122081A (ja) 1984-07-10 1986-01-30 Mitsui Toatsu Chem Inc ヒダントイン化合物の製造法
DE3685626T2 (de) 1985-09-26 1993-01-28 Beckmann Research Inst Of The Sequenzierung von peptiden.
IE940525L (en) 1988-05-25 1989-11-25 Warner Lambert Co Known and selected novel arylmethylenyl derivatives of¹thiazolidinones, imidazolidinones and oxazolidinones useful¹as antiallergy agents and antiinflammatory agents
JPH0219363A (ja) 1988-07-06 1990-01-23 Fujisawa Pharmaceut Co Ltd イミダゾリジン誘導体
WO1990004183A1 (en) 1988-10-07 1990-04-19 Commonwealth Scientific And Industrial Research Organisation Method for preparation of thiohydantoins and for protein sequence analysis
ATE94906T1 (de) 1989-01-02 1993-10-15 Ruetgerswerke Ag Verfahren zur herstellung von l-alphaaminos|uren.
JPH054910A (ja) 1990-07-31 1993-01-14 Nikka Chem Co Ltd 化粧料組成物
KR100222634B1 (ko) 1990-08-31 1999-10-01 로즈 암스트롱, 크리스틴 에이. 트러트웨인 콜레시스토키닌길항제,그의제조방법및치료학적용도
NZ242065A (en) 1991-03-26 1996-06-25 Csl Ltd Delayed release implant having a degradable or rupturable polymeric coating
US5693643A (en) 1991-09-16 1997-12-02 Merck & Co., Inc. Hydantoin and succinimide-substituted derivatives of spiroindanylcamphorsulfonyl oxytocin antagonists
CH683995A5 (fr) 1991-12-02 1994-06-30 Nestle Sa (Alcoxy-1-éthenyl)-2-pyrroline-1 et procédé de préparation d'acétyl-2-pyrroline-1.
CA2083891A1 (en) * 1991-12-03 1993-06-04 Angus Murray Macleod Heterocyclic compounds, compositions containing them and their use in therapy
AU4424496A (en) 1995-03-27 1996-10-16 Warner-Lambert Company A method for the synthesis of mixtures of compounds
US6166054A (en) 1995-03-31 2000-12-26 Nihon Nohyaku Co., Ltd. Agricultural and horticultural disease controller and a method for controlling the diseases
US6846839B1 (en) 1995-06-07 2005-01-25 Sugen, Inc. Methods for treating diseases and disorders related to unregulated angiogenesis and/or vasculogenesis
FR2750862B1 (fr) * 1996-07-12 1998-10-16 Dupin Jean Pierre Utilisation d'heterocycles diazotes fusionnes avec un systeme aromatique ou heteroaromatique pour le traitement des maladies thrombo-emboliques
EP0930305B1 (en) 1996-09-30 2003-05-14 Nihon Nohyaku Co., Ltd. 1,2,3-thiadiazole derivatives and salts thereof, disease controlling agents for agricultural and horticultural use, and method for the use thereof
WO1998039303A1 (en) 1997-03-03 1998-09-11 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
US6355664B1 (en) * 1997-03-03 2002-03-12 Boehringer Ingelheim Pharmaceuticals, Inc. Phenylpyrrolidines, phenylimidazolidines, 3-phenyl-1,3-oxizolidines and 3-phenyl-1,3-thiazolidines and their use in the treatment of inflammatory disease
JP2001524121A (ja) * 1997-05-08 2001-11-27 アグレボ・ユー・ケイ・リミテツド 殺菌剤
ATE238661T1 (de) 1998-07-30 2003-05-15 Nihon Nohyaku Co Ltd Fungizide zusammensetzung enthaltend ein 1,2,3- thiadiazolderivat sowie deren verwendung
US6756394B1 (en) 1999-10-15 2004-06-29 President And Fellow Of Harvard College Small molecule inhibitors of necrosis
WO2001028493A2 (en) 1999-10-15 2001-04-26 President And Fellows Of Harvard College Small molecule inhibitors of necrosis
US6706766B2 (en) 1999-12-13 2004-03-16 President And Fellows Of Harvard College Small molecules used to increase cell death
EP1275646A4 (en) 2000-03-30 2003-05-28 Sagami Chem Res INDOLYLPYRROL DERIVATIVES AND CELL DEATH INHIBITORS
US20020155172A1 (en) 2000-04-07 2002-10-24 Junying Yuan Methods and compounds for decreasing cell toxicity or death
GB0011071D0 (en) 2000-05-08 2000-06-28 Novartis Ag Organic compounds
DE10031390A1 (de) * 2000-07-03 2002-01-17 Knoll Ag Pyrimidinderivate und ihre Verwendung zur Prophylaxe und Therapie der zerebralen Ischämie
JP2002105081A (ja) * 2000-07-28 2002-04-10 Nikken Chem Co Ltd 新規チオフェンニ環化合物
WO2002044157A2 (en) * 2000-12-01 2002-06-06 Iconix Pharmaceuticals, Inc. Parb inhibitors
JP4529338B2 (ja) 2001-03-08 2010-08-25 味の素株式会社 ヒダントイナーゼをコードするｄｎａ、ｎ−カルバミル−ｌ−アミノ酸ハイドロラーゼをコードするｄｎａ、組み換えｄｎａ、形質転換された細胞、タンパク質の製造方法および光学活性アミノ酸の製造方法
US7868204B2 (en) * 2001-09-14 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
DE10150325A1 (de) 2001-10-15 2003-04-24 Degussa Verfahren zur Herstellung oder Beschichtung von Granulaten, Vorrichtung zur Durchführung des Verfahrens und hiernach erhältliche Granulate
JP2005515173A (ja) * 2001-10-31 2005-05-26 バイエル・ヘルスケア・アクチェンゲゼルシャフト ピリミド［４，５−ｂ］インドール誘導体
RU2004118719A (ru) 2001-11-22 2005-03-27 Оно Фармасьютикал Ко., Лтд. (Jp) Производные пиперидин-2-она и фармацевтические композиции, содержащие такие соединения в качестве активного ингредиента
US6797708B2 (en) 2001-12-03 2004-09-28 Wyeth Inhibitors of cytosolic phospholipase A2
JP3659224B2 (ja) 2001-12-26 2005-06-15 村田機械株式会社 インターネットファクシミリ装置
WO2003057214A1 (en) 2001-12-28 2003-07-17 Somatocor Pharmaceuticals, Inc. Imidazolidin-2,4-dione derivatives as non-peptide somatostatin receptor ligands
FR2850652B1 (fr) 2003-01-31 2008-05-30 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
GB0302671D0 (en) 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
US7320986B2 (en) 2003-03-07 2008-01-22 Abbott Labortories Fused tri and tetra-cyclic pyrazole kinase inhibitors
EP1606285A4 (en) * 2003-03-27 2009-03-18 Lankenau Inst Medical Res NEW IDO HEMMER AND APPLICATION PROCEDURES
CN1794986B (zh) * 2003-03-27 2012-09-05 兰肯瑙医学研究所 治疗癌症的新药物
US7465739B2 (en) * 2003-06-10 2008-12-16 Solvay Pharmaceuticals B.V. Compounds and their use in therapy
CA2536622C (en) 2003-08-29 2014-02-11 The Brigham And Women's Hospital, Inc. Inhibitors of cellular necrosis
WO2005028664A2 (en) 2003-09-17 2005-03-31 University Of Massachusetts Modulation of programmed necrosis
DE10348023A1 (de) 2003-10-15 2005-05-19 Imtm Gmbh Neue Alanyl-Aminopeptidasen-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
US6887993B1 (en) 2003-11-12 2005-05-03 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
JP2007529422A (ja) * 2004-01-29 2007-10-25 エリクシアー ファーマシューティカルズ， インコーポレイテッド 抗ウイルス治療
CN1922171B (zh) * 2004-02-26 2012-10-17 Aska制药株式会社 嘧啶衍生物
WO2005115147A2 (en) 2004-05-18 2005-12-08 Merck & Co., Inc. Hiv reverse transcriptase inhibitors
WO2006012642A2 (en) 2004-07-30 2006-02-02 Exelixis, Inc. Pyrrole derivatives as pharmaceutical agents
JP2008517061A (ja) * 2004-10-20 2008-05-22 コンパス ファーマシューティカルズ リミティド ライアビリティ カンパニー 抗腫瘍剤としての化合物及びそれらの使用
EP1851213A4 (en) 2005-02-10 2010-10-06 Merck Sharp & Dohme INHIBITORS OF MITOTIC KINESINE
JP2009513576A (ja) * 2005-10-11 2009-04-02 インターミューン・インコーポレーテッド ウィルス複製のインヒビター
US20090022694A1 (en) * 2005-10-18 2009-01-22 Distefano Peter Sirt1 inhibition
WO2007059905A2 (en) * 2005-11-25 2007-05-31 Develogen Aktiengesellschaft Thienopyrimidines treating inflammatory diseases
JP2009521454A (ja) 2005-12-20 2009-06-04 プレジデント・アンド・フエローズ・オブ・ハーバード・カレツジ 化合物、スクリーニング、および処置方法
AR056882A1 (es) 2006-02-01 2007-10-31 Bayer Cropscience Sa Derivados del fungicida n- cicloalquil- bencil- amida
JP2009542777A (ja) 2006-07-13 2009-12-03 ４エスツェー アクチェンゲゼルシャフト ベンゾピラノピラゾール
AU2007307044B2 (en) 2006-10-10 2014-03-20 President And Fellows Of Harvard College Compounds, screens, and methods of treatment
CN100430403C (zh) * 2006-10-13 2008-11-05 中国科学院上海有机化学研究所 3-芳基-5,6-取代噻吩并嘧啶-4-羰基-2-巯基乙腈、合成方法和用途
EP2099792A1 (en) * 2006-11-20 2009-09-16 Alantos Pharmaceuticals Holding, Inc. Heterotricyclic metalloprotease inhibitors
CN101743008A (zh) * 2007-05-23 2010-06-16 西佳技术公司 用于治疗或预防登革热感染的抗病毒药
CA2696349A1 (en) 2007-08-15 2009-02-19 President And Fellows Of Harvard College Heterocyclic inhibitors of necroptosis
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2009109983A1 (en) * 2008-03-03 2009-09-11 National Chemical Laboratory Thieno[2,3-d]-pyrimidine-4(3h)-one compounds with antifungal properties and process thereof
GB0810542D0 (en) 2008-06-09 2008-07-16 Element Six Production Pty Ltd Cubic boron nitride compact
WO2010075290A1 (en) 2008-12-22 2010-07-01 President And Fellows Of Harvard College Unsaturated heterocyclic inhibitors of necroptosis
CA2772760A1 (en) 2008-12-23 2010-07-01 President And Fellows Of Harvard College Small molecule inhibitors of necroptosis
WO2014152182A1 (en) 2013-03-15 2014-09-25 President And Fellows Of Harvard College Deuterated heterocyclic inhibitors of necroptosis
US20160024098A1 (en) 2013-03-15 2016-01-28 President And Fellows Of Harvard College Hybrid necroptosis inhibitors
EP3229807A4 (en) 2014-12-11 2018-10-17 President and Fellows of Harvard College Inhibitors of cellular necrosis and related methods

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6300349B1 (en) * 1995-09-19 2001-10-09 Solomon B. Margolin Inhibition of tumor necrosis factor alpha
US20080045541A1 (en) * 2004-02-19 2008-02-21 Bayer-Healthcare Ag Dihydropyridinone Derivatives
US20070099936A1 (en) * 2005-11-01 2007-05-03 Hiayan Bian Dihydroisoindolones As Allosteric Modulators Of Glucokinase

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2381775A4 *

Cited By (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8741942B2 (en) 2003-08-29 2014-06-03 President And Fellows Of Harvard College Inhibitors of cellular necrosis
US8143300B2 (en) 2003-08-29 2012-03-27 President And Fellows Of Harvard College Inhibitors of cellular necrosis
US8278344B2 (en) 2007-08-15 2012-10-02 The Brigham And Women's Hospital, Inc. Heterocyclic inhibitors of necroptosis
US9108955B2 (en) 2007-08-15 2015-08-18 President And Fellows Of Harvard College Heterocyclic inhibitors of necroptosis
US8658689B2 (en) 2007-08-15 2014-02-25 President And Fellows Of Harvard College Heterocyclic inhibitors of necroptosis
USRE47142E1 (en) 2008-06-03 2018-11-27 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US8969347B2 (en) 2008-06-03 2015-03-03 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US9290450B2 (en) 2008-06-03 2016-03-22 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US9586880B2 (en) 2008-12-23 2017-03-07 President And Fellows Of Harvard College Small molecule inhibitors of necroptosis
US8598156B2 (en) 2010-03-25 2013-12-03 Glaxosmithkline Llc Chemical compounds
US9750815B2 (en) 2010-07-26 2017-09-05 Gnosis Spa Composition comprising shellac and/or a salt thereof and sodium starch glycolate
US8569331B2 (en) 2010-11-01 2013-10-29 Arqule, Inc. Substituted benzo[f]lmidazo[1,2-d]pyrido[2,3-b][1,4]diazepine compounds
US9643977B2 (en) 2011-03-11 2017-05-09 President And Fellows Of Harvard College Necroptosis inhibitors and methods of use therefor
KR101410332B1 (ko) 2012-02-29 2014-06-24 코아스템(주) 중간엽 기질세포 배양용 항산화 조성물 및 이의 용도
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
US10376497B2 (en) 2012-10-02 2019-08-13 Intermune, Inc. Anti-fibrotic pyridinones
US10898474B2 (en) 2012-10-02 2021-01-26 Intermune, Inc. Anti-fibrotic pyridinones
US9359379B2 (en) 2012-10-02 2016-06-07 Intermune, Inc. Anti-fibrotic pyridinones
US9675593B2 (en) 2012-10-02 2017-06-13 Intermune, Inc. Anti-fibrotic pyridinones
US9394285B2 (en) 2013-03-15 2016-07-19 Pfizer Inc. Indole and indazole compounds that activate AMPK
EP2968276A4 (en) * 2013-03-15 2017-02-15 President and Fellows of Harvard College Hybrid necroptosis inhibitors
US9725452B2 (en) 2013-03-15 2017-08-08 Presidents And Fellows Of Harvard College Substituted indoles and pyrroles as RIP kinase inhibitors
US10005739B2 (en) 2013-10-23 2018-06-26 Chugai Seiyaku Kabushiki Kaisha Quinazolinone and isoquinolinone derivative
US10544161B2 (en) 2014-04-02 2020-01-28 Intermune, Inc. Anti-fibrotic pyridinones
US10233195B2 (en) 2014-04-02 2019-03-19 Intermune, Inc. Anti-fibrotic pyridinones
US9499521B2 (en) 2014-12-11 2016-11-22 President And Fellows Of Harvard College Inhibitors of cellular necrosis and related methods
US9944628B2 (en) 2014-12-11 2018-04-17 President And Fellows Of Harvard College Inhibitors of cellular necrosis and related methods
US10508102B2 (en) 2014-12-11 2019-12-17 President And Fellows Of Harvard College Inhibitors of cellular necrosis and related methods
AU2015371824B2 (en) * 2014-12-24 2019-09-19 National Institute Of Biological Sciences, Beijing Necrosis inhibitors
US20170304237A1 (en) * 2014-12-24 2017-10-26 National Institute Of Biological Sciences, Beijing Necrosis Inhibitors
KR20170098904A (ko) * 2014-12-24 2017-08-30 내셔널 인스티튜트 오브 바이올로지칼 사이언시스, 베이징 괴사 억제제
KR102596723B1 (ko) 2014-12-24 2023-11-01 내셔널 인스티튜트 오브 바이올로지칼 사이언시스, 베이징 괴사 억제제
US10092529B2 (en) * 2014-12-24 2018-10-09 National Institute Of Biological Sciences, Beijing Necrosis inhibitors
EP3224237A4 (en) * 2014-12-24 2018-02-07 National Institute Of Biological Sciences, Beijing Necrosis inhibitors
WO2016101885A1 (en) 2014-12-24 2016-06-30 National Institute Of Biological Sciences, Beijing Necrosis inhibitors
US10555920B2 (en) 2014-12-24 2020-02-11 National Institute Of Biological Sciences, Beijing Necrosis inhibitors
US11478438B2 (en) * 2014-12-24 2022-10-25 National Institute Of Biological Sciences, Beijing Necrosis inhibitors
AU2015371822B2 (en) * 2014-12-24 2020-04-09 National Institute Of Biological Sciences, Beijing Necrosis inhibitors
WO2016101887A1 (en) * 2014-12-24 2016-06-30 National Institute Of Biological Sciences, Beijing Necrosis inhibitors
US20200182617A1 (en) * 2014-12-24 2020-06-11 National Institute Of Biological Sciences, Beijing Necrosis Inhibitors
US10899716B2 (en) 2015-05-19 2021-01-26 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
WO2016185423A1 (en) 2015-05-19 2016-11-24 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
US10590085B2 (en) 2015-05-19 2020-03-17 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
US11485710B2 (en) 2015-05-19 2022-11-01 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
US11168068B2 (en) 2016-07-18 2021-11-09 Janssen Pharmaceutica Nv Tau PET imaging ligands
US12006302B2 (en) 2016-07-18 2024-06-11 Janssen Pharmaceutica Nv Tau PET imaging ligands
IL275739B1 (en) * 2017-12-31 2024-06-01 Evergreen Biosciences Preparations for cryopreservation and methods of their use
US12053454B2 (en) 2017-12-31 2024-08-06 Evergreen Biosciences Compositions for cryopreservation and methods of use thereof
IL275739B2 (en) * 2017-12-31 2024-10-01 Evergreen Biosciences Compositions for cryopreservation and methods of use thereof
WO2020103859A1 (en) 2018-11-20 2020-05-28 Sironax Ltd RIP1 Inhibitors
US11718612B2 (en) 2019-09-06 2023-08-08 Board Of Regents, The University Of Texas System Inhibitors of receptor interacting protein kinase I for the treatment of disease
US11753381B2 (en) 2019-09-27 2023-09-12 Board Of Regents, The University Of Texas System Inhibitors of receptor interacting protein kinase I for the treatment of disease
US12286406B2 (en) 2019-09-27 2025-04-29 Board Of Regents, The University Of Texas System Inhibitors of receptor interacting protein kinase I for the treatment of disease
US11690850B2 (en) 2019-11-26 2023-07-04 Board Of Regents, The University Of Texas System Inhibitors of receptor interacting protein kinase I for the treatment of disease
WO2021233397A1 (en) 2020-05-20 2021-11-25 Sironax Ltd. Piperazine cyclic ureas
US12454529B2 (en) 2020-05-20 2025-10-28 Sironax Ltd. Piperazine cyclic ureas

Also Published As

Publication number Publication date
US20120122889A1 (en) 2012-05-17
EP2381775A4 (en) 2012-08-15
HK1223272A1 (en) 2017-07-28
BRPI0923126A2 (pt) 2021-09-08
AU2009329879A1 (en) 2011-08-11
EP2381775A1 (en) 2011-11-02
US9586880B2 (en) 2017-03-07
CN104803986A (zh) 2015-07-29
US20170305824A1 (en) 2017-10-26
AU2016202262A1 (en) 2016-05-12
US20140024657A1 (en) 2014-01-23
US20190135718A1 (en) 2019-05-09
JP6178777B2 (ja) 2017-08-09
EP3000468A1 (en) 2016-03-30
HK1212973A1 (zh) 2016-06-24
CN102316735A (zh) 2012-01-11
JP2012513481A (ja) 2012-06-14
JP2015061853A (ja) 2015-04-02
CA2772760A1 (en) 2010-07-01

Similar Documents

Publication Publication Date Title
WO2010075561A1 (en) Small molecule inhibitors of necroptosis
WO2010075290A1 (en) Unsaturated heterocyclic inhibitors of necroptosis
JP5645663B2 (ja) ネクロトーシスのヘテロ環式抑制剤
JPS6322080A (ja) 薬理学的に活性な１，５−ジアリ−ル−３−置換−ピラゾ−ル類およびそれらを製造する方法
AU2019233698B2 (en) Novel calcium salt polymorphs as anti-inflammatory, immunomodulatory and anti-proliferatory agents
JPS5840956B2 (ja) アミノアルキルフラン誘導体、その製法およびそれを含有する医薬組成物
CN111548320B (zh) 一类1，3，4-噁二唑酰肼类化合物及其制备方法和应用
US5110831A (en) Vinylogous hydroxamic acids and derivatives thereof as 5-lipoxygenase inhibitors
US5204365A (en) Substituted diphenylmethane derivatives as analgesic or anti-inflammatory agents
SK2722002A3 (en) Use of bis-sulfonamides for producing medicaments used for preventing or treating hyperlipidaemia
JPH0692360B2 (ja) 新規のベンゾセレナゾリノン化合物、これらを調製するプロセスおよびそれらを含む薬剤組成物
US3849575A (en) Thiosemicarbazones as anti-fertility agents
FI56528C (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbar 5-n-pyrrylsalicylsyra
JPWO1997009047A1 (ja) ヘリコバクターの感染に起因する疾患の治療剤

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980156914.4

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09835866

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2011543689

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009329879

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 5352/CHENP/2011

Country of ref document: IN

Ref document number: 2009835866

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2009329879

Country of ref document: AU

Date of ref document: 20091223

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13141545

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2772760

Country of ref document: CA

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: PI0923126

Country of ref document: BR

ENP Entry into the national phase

Ref document number: PI0923126

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20110622